Retinal vessel caliber as a potential marker of treatment outcome in patients with proliferative diabetic retinopathy

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskningpeer review

Resumé

Title of abstract:
Retinal vessel caliber as a potential marker of treatment outcome in patients with proliferative diabetic retinopathy

Design of study:
Three months prospective, interventional clinical study.

Purpose:
The retinal vascular tree can be measured non-invasively and summarized into the central retinal artery and vein equivalent (CRAE and CRVE). The purpose of this study was to evaluate retinal calibers as biomarkers for disease activity 3 months after panretinal photocoagulation (PRP) in patients with proliferative diabetic retinopathy (PDR).

Methods:
Fifty one eyes from 40 newly diagnosed patients with PDR were included. At baseline, all patients received standard PRP treatment by a navigated laser (NAVILAS®, OD-OS GmbH, Berlin, Germany). Wide-field fundus fluorescein angiography (Optomap, Optos PLC., Dunfermline, Scotland, UK) was performed at BL to verify diagnosis of PDR and again after 3 month of follow-up (M3) to assess disease activity. At M3, patients were categorized according to PDR-activity: Progression (Group 1, n=15) or stability/regression (Group 2, n=36). Semi-automated software (IVAN, University of Wisconsin, Madison, Wisconsin, USA) was used to measure CRAE, CRVE and the arterio-venous (AV) ratio. All measurements were performed by a certified grader.

Results:
Median age and duration of diabetes were 52 years and 20 years, respectively, and 65% were male. Median HbA1c was 63 mmol/mol, and the blood pressure was 155/82 mmHg. There were no differences between Group 1 and 2 in number of laser spots (median, 1661 vs. 1531, p=0.29) or total laser energy delivered (median, 15 joule vs. 13 joule, p=0.09).
At baseline, patients in Group 1 and 2 did not differ in according to median CRAE (147.0m vs. 140.1m, p=0.19), CRVE (216.4m vs. 221.7m, p=0.19) or AVR (0.65 vs. 0.65, p=0.81). This was also found at M3 (CRAE: 139.0m vs. 138.5m, p=0.76, CRVE: 220.4m vs. 211.0m, p=0.06, AVR: 0.61 vs. 0.67, p=0.14). However, from BL to M3 patients in Group 1 developed a lower CRAE (-5.9m, p=0.003) and a lower AVR (-0.02, p=0.01). Likewise, patients in Group 2 developed a lower CRVE (-4.7m, p=0.03).

Conclusions:
We found that arteriolar constriction is a sign for PDR-activity, and that venular constriction is a sign for PDR-stability 3 months after PRP treatment. This identifies retinal calibers as a promising biomarker for treatment outcome in patients with proliferative diabetic retinopathy.
OriginalsprogDansk
Publikationsdato11. sep. 2016
StatusUdgivet - 11. sep. 2016
BegivenhedEURETINA 2016 - Copenhagen, Danmark
Varighed: 8. sep. 201611. sep. 2016

Konference

KonferenceEURETINA 2016
LandDanmark
ByCopenhagen
Periode08/09/201611/09/2016

Citer dette

@conference{666844115b2a4109a122388516d5dd90,
title = "Retinal vessel caliber as a potential marker of treatment outcome in patients with proliferative diabetic retinopathy",
abstract = "Title of abstract: Retinal vessel caliber as a potential marker of treatment outcome in patients with proliferative diabetic retinopathy Design of study: Three months prospective, interventional clinical study.Purpose: The retinal vascular tree can be measured non-invasively and summarized into the central retinal artery and vein equivalent (CRAE and CRVE). The purpose of this study was to evaluate retinal calibers as biomarkers for disease activity 3 months after panretinal photocoagulation (PRP) in patients with proliferative diabetic retinopathy (PDR).Methods: Fifty one eyes from 40 newly diagnosed patients with PDR were included. At baseline, all patients received standard PRP treatment by a navigated laser (NAVILAS{\circledR}, OD-OS GmbH, Berlin, Germany). Wide-field fundus fluorescein angiography (Optomap, Optos PLC., Dunfermline, Scotland, UK) was performed at BL to verify diagnosis of PDR and again after 3 month of follow-up (M3) to assess disease activity. At M3, patients were categorized according to PDR-activity: Progression (Group 1, n=15) or stability/regression (Group 2, n=36). Semi-automated software (IVAN, University of Wisconsin, Madison, Wisconsin, USA) was used to measure CRAE, CRVE and the arterio-venous (AV) ratio. All measurements were performed by a certified grader.Results: Median age and duration of diabetes were 52 years and 20 years, respectively, and 65{\%} were male. Median HbA1c was 63 mmol/mol, and the blood pressure was 155/82 mmHg. There were no differences between Group 1 and 2 in number of laser spots (median, 1661 vs. 1531, p=0.29) or total laser energy delivered (median, 15 joule vs. 13 joule, p=0.09).At baseline, patients in Group 1 and 2 did not differ in according to median CRAE (147.0m vs. 140.1m, p=0.19), CRVE (216.4m vs. 221.7m, p=0.19) or AVR (0.65 vs. 0.65, p=0.81). This was also found at M3 (CRAE: 139.0m vs. 138.5m, p=0.76, CRVE: 220.4m vs. 211.0m, p=0.06, AVR: 0.61 vs. 0.67, p=0.14). However, from BL to M3 patients in Group 1 developed a lower CRAE (-5.9m, p=0.003) and a lower AVR (-0.02, p=0.01). Likewise, patients in Group 2 developed a lower CRVE (-4.7m, p=0.03).Conclusions: We found that arteriolar constriction is a sign for PDR-activity, and that venular constriction is a sign for PDR-stability 3 months after PRP treatment. This identifies retinal calibers as a promising biomarker for treatment outcome in patients with proliferative diabetic retinopathy.",
author = "Vergmann, {Anna Stage} and Torp, {Thomas Lee} and Kristian Lundberg and Tunde Peto and Jakob Grauslund",
year = "2016",
month = "9",
day = "11",
language = "Dansk",
note = "EURETINA 2016 ; Conference date: 08-09-2016 Through 11-09-2016",

}

Retinal vessel caliber as a potential marker of treatment outcome in patients with proliferative diabetic retinopathy. / Vergmann, Anna Stage ; Torp, Thomas Lee; Lundberg, Kristian ; Peto, Tunde ; Grauslund, Jakob.

2016. Poster session præsenteret på EURETINA 2016, Copenhagen, Danmark.

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskningpeer review

TY - CONF

T1 - Retinal vessel caliber as a potential marker of treatment outcome in patients with proliferative diabetic retinopathy

AU - Vergmann, Anna Stage

AU - Torp, Thomas Lee

AU - Lundberg, Kristian

AU - Peto, Tunde

AU - Grauslund, Jakob

PY - 2016/9/11

Y1 - 2016/9/11

N2 - Title of abstract: Retinal vessel caliber as a potential marker of treatment outcome in patients with proliferative diabetic retinopathy Design of study: Three months prospective, interventional clinical study.Purpose: The retinal vascular tree can be measured non-invasively and summarized into the central retinal artery and vein equivalent (CRAE and CRVE). The purpose of this study was to evaluate retinal calibers as biomarkers for disease activity 3 months after panretinal photocoagulation (PRP) in patients with proliferative diabetic retinopathy (PDR).Methods: Fifty one eyes from 40 newly diagnosed patients with PDR were included. At baseline, all patients received standard PRP treatment by a navigated laser (NAVILAS®, OD-OS GmbH, Berlin, Germany). Wide-field fundus fluorescein angiography (Optomap, Optos PLC., Dunfermline, Scotland, UK) was performed at BL to verify diagnosis of PDR and again after 3 month of follow-up (M3) to assess disease activity. At M3, patients were categorized according to PDR-activity: Progression (Group 1, n=15) or stability/regression (Group 2, n=36). Semi-automated software (IVAN, University of Wisconsin, Madison, Wisconsin, USA) was used to measure CRAE, CRVE and the arterio-venous (AV) ratio. All measurements were performed by a certified grader.Results: Median age and duration of diabetes were 52 years and 20 years, respectively, and 65% were male. Median HbA1c was 63 mmol/mol, and the blood pressure was 155/82 mmHg. There were no differences between Group 1 and 2 in number of laser spots (median, 1661 vs. 1531, p=0.29) or total laser energy delivered (median, 15 joule vs. 13 joule, p=0.09).At baseline, patients in Group 1 and 2 did not differ in according to median CRAE (147.0m vs. 140.1m, p=0.19), CRVE (216.4m vs. 221.7m, p=0.19) or AVR (0.65 vs. 0.65, p=0.81). This was also found at M3 (CRAE: 139.0m vs. 138.5m, p=0.76, CRVE: 220.4m vs. 211.0m, p=0.06, AVR: 0.61 vs. 0.67, p=0.14). However, from BL to M3 patients in Group 1 developed a lower CRAE (-5.9m, p=0.003) and a lower AVR (-0.02, p=0.01). Likewise, patients in Group 2 developed a lower CRVE (-4.7m, p=0.03).Conclusions: We found that arteriolar constriction is a sign for PDR-activity, and that venular constriction is a sign for PDR-stability 3 months after PRP treatment. This identifies retinal calibers as a promising biomarker for treatment outcome in patients with proliferative diabetic retinopathy.

AB - Title of abstract: Retinal vessel caliber as a potential marker of treatment outcome in patients with proliferative diabetic retinopathy Design of study: Three months prospective, interventional clinical study.Purpose: The retinal vascular tree can be measured non-invasively and summarized into the central retinal artery and vein equivalent (CRAE and CRVE). The purpose of this study was to evaluate retinal calibers as biomarkers for disease activity 3 months after panretinal photocoagulation (PRP) in patients with proliferative diabetic retinopathy (PDR).Methods: Fifty one eyes from 40 newly diagnosed patients with PDR were included. At baseline, all patients received standard PRP treatment by a navigated laser (NAVILAS®, OD-OS GmbH, Berlin, Germany). Wide-field fundus fluorescein angiography (Optomap, Optos PLC., Dunfermline, Scotland, UK) was performed at BL to verify diagnosis of PDR and again after 3 month of follow-up (M3) to assess disease activity. At M3, patients were categorized according to PDR-activity: Progression (Group 1, n=15) or stability/regression (Group 2, n=36). Semi-automated software (IVAN, University of Wisconsin, Madison, Wisconsin, USA) was used to measure CRAE, CRVE and the arterio-venous (AV) ratio. All measurements were performed by a certified grader.Results: Median age and duration of diabetes were 52 years and 20 years, respectively, and 65% were male. Median HbA1c was 63 mmol/mol, and the blood pressure was 155/82 mmHg. There were no differences between Group 1 and 2 in number of laser spots (median, 1661 vs. 1531, p=0.29) or total laser energy delivered (median, 15 joule vs. 13 joule, p=0.09).At baseline, patients in Group 1 and 2 did not differ in according to median CRAE (147.0m vs. 140.1m, p=0.19), CRVE (216.4m vs. 221.7m, p=0.19) or AVR (0.65 vs. 0.65, p=0.81). This was also found at M3 (CRAE: 139.0m vs. 138.5m, p=0.76, CRVE: 220.4m vs. 211.0m, p=0.06, AVR: 0.61 vs. 0.67, p=0.14). However, from BL to M3 patients in Group 1 developed a lower CRAE (-5.9m, p=0.003) and a lower AVR (-0.02, p=0.01). Likewise, patients in Group 2 developed a lower CRVE (-4.7m, p=0.03).Conclusions: We found that arteriolar constriction is a sign for PDR-activity, and that venular constriction is a sign for PDR-stability 3 months after PRP treatment. This identifies retinal calibers as a promising biomarker for treatment outcome in patients with proliferative diabetic retinopathy.

UR - http://www.euretina.org/abstracts.asp

M3 - Poster

ER -